170142-38-8

Basic information

• Product Name: Pyridazino[4,5-b]quinoline-1,4,10(5H)-trione, 7-chloro-2,3-dihydro-2-(4-hydroxy-2-methylphenyl)-
• CAS NO: 170142-38-8
• Molecular Formula: C18H12ClN3O4
• Molecular Weight: 369.75900
• Mol File: 170142-38-8.mol
• Article Data: 3

Chemical Properties

• Melting Point: 287 °C
• Density: 1.65±0.1 g/cm3(Predicted)
• CAS DataBase Reference: Pyridazino[4,5-b]quinoline-1,4,10(5H)-trione, 7-chloro-2,3-dihydro-2-(4-hydroxy-2-methylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridazino[4,5-b]quinoline-1,4,10(5H)-trione, 7-chloro-2,3-dihydro-2-(4-hydroxy-2-methylphenyl)-(170142-38-8)
• EPA Substance Registry System: Pyridazino[4,5-b]quinoline-1,4,10(5H)-trione, 7-chloro-2,3-dihydro-2-(4-hydroxy-2-methylphenyl)-(170142-38-8)

Safety Data

• Hazardous Substances Data: 170142-38-8(Hazardous Substances Data)

Upstream product

• 179543-90-9 7-chloro-3-methoxycarbonyl-4-oxo-1,4-dihydroquinoline-2-carbonyl chloride 
• 93048-16-9 1-(4-methoxy-2-methylphenyl)-hydrazine hydrochloride 
• 102-50-1 2-methyl-4-methoxyaniline 
• 170142-20-8 7-chloro-4-hydroxy-2-(4-methoxy-2-methylphenyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione 
• 123-41-1 cholin hydroxide 

Relevant articles and documents

Pyridazino quinoline compounds

The invention relates to pyridazinoquinoline compounds of the formulas B and B′ wherein Ring A is selected from an ortho fused aromatic or heteroaromatic five- or six-membered ring and R1, R3and R4are substituents selected from halo, OH, OCF3, NO2, CN, NR′R″, SO2NR′R″, SOmR′alkyl, and a variety of alkyl, aryl, heterocyclic and heteroaryl groups, to pharmaceutical compositions containing them and to methods utilizing them for the treatment of neurological disorders.

Pyridazion quinoline compounds

The present invention relates to compounds, pharmaceutical compositions and methods of using compounds of formula (I) in the treatment and/or prevention of certain diseases or conditions. In formula (I), A is chosen from ortho substituted aryl or heteroaryl species, X is chosen from --OH, --SH, NHR and R 1 or R 2 is chosen from --(CH 2) n L wherein L may be selected from a variety of substituents including aryl, heteroaryl and heterocyclic groups. The compounds are useful in treating and/or preventing neurological disorders associated with excitatory amino acids. STR1